FDA calendar · April 2022 · built from SEC filings

PDUFA dates April 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in April 2022. The FDA calendar also recorded 26 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in April 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

April 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Apr 2022Month disclosedSULANDA® (surufatinib)HCMComplete Response LetterpNETs and non-pancreatic NETsCRL issuedSEC Form 10-K
Apr 2022Month disclosedKIMMTRAK (tebentafusp)IMCRFDA approvalunresectable or metastatic uveal melanomaApprovedSEC Form 10-Q
April 5, 2022IGALMI® (dexmedetomidine)BTAIQFDA approval—ApprovedSEC Form 10-Q
April 5, 2022Piqray (alpelisib)NVSFDA approval—ApprovedopenFDA Drugs@FDA
April 6, 2022talabostat (BXCL701)BTAIQFDA approval—ApprovedSEC Form 10-Q
April 11, 2022Xigduo Xr (dapagliflozin; metformin hydrochloride)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
April 11, 2022Nurtec Odt (rimegepant sulfate)PFELabel expansion—ApprovedopenFDA Drugs@FDA
April 13, 2022MVASI® (bevacizumab)AMRXFDA approval—ApprovedSEC Form 10-Q
April 15, 2022UZEDY (risperidone)TEVAComplete Response Letter—CRL issuedFDA Complete Response Letters
April 18, 2022Lupron Depot (leuprolide acetate)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
April 18, 2022Cyclophosphamide (cyclophosphamide)RDYComplete Response Letter—CRL issuedFDA Complete Response Letters
April 25, 2022Veklury (remdesivir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
April 25, 2022EpsolaySLGLFDA approval—ApprovedSEC Form 10-K
April 27, 2022Ultomiris (ravulizumab-cwvz)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
April 27, 2022Epclusa (sofosbuvir; velpatasvir)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
April 28, 2022Camzyos® (mavacamten)BMYFDA approvalTo treat certain classes of obstructive hypertrophic cardiomyopathyApprovedFDA Novel Drug Approvals
April 28, 2022Ninlaro (ixazomib citrate)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
April 29, 2022RINVOQ® (upadacitinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
April 29, 2022Loqtorzi (toripalimab-tpzi)CHRSComplete Response Letter—CRL issuedFDA Complete Response Letters
April 29, 2022Ermeza (levothyroxine sodium)VTRSFDA approval—ApprovedopenFDA Drugs@FDA

April 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Apr 2022Month disclosed—PLXTopline readout—PositiveSEC Form 10-Q
April 4, 2022Elfabrio (pegunigalsidase alfa)PLXTopline readoutFabry diseasePositivesec_424b

April 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Apr 2022Month disclosedWAKIX® (pitolisant)HRMYTrial start—CompletedSEC Form 10-K
Apr 2022Month disclosedbitopertin (DISC-1459)IRONTrial start—CompletedSEC Form 10-Q
Apr 2022Month disclosedruxotemitide (VP-315)VRCATrial startbiopsy proven BCCCompletedSEC Form 10-K
Apr 2022Month disclosedzalifrelimab (AGEN1884)URGNTrial start—CompletedSEC Form 10-K

Questions

What PDUFA dates are in April 2022?

0 PDUFA dates fell in April 2022. The FDA calendar also recorded 26 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.